Avalo-Final_Black-01.jpg
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 07, 2022 07:30 ET | Avalo Therapeutics
Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Entered into agreement to sell future economic rights to previously out-licensed...
Avalo-Final_Black-01.jpg
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
November 07, 2022 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future...
Avalo-Final_Black-01.jpg
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
September 06, 2022 07:00 ET | Avalo Therapeutics
Strategy focused on LIGHT-signaling network targets WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T...
Avalo-Final_Black-01.jpg
Avalo to Present at the H.C. Wainwright Global Investment Conference
September 01, 2022 07:00 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will...
Avalo-Final_Black-01.jpg
Avalo Therapeutics Announces Board Changes
August 11, 2022 16:01 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice...
Avalo-Final_Black-01.jpg
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 04, 2022 07:30 ET | Avalo Therapeutics
Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2...
Avalo-Final_Black-01.jpg
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
August 02, 2022 07:30 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3,...
Avalo-Final_Black-01.jpg
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
August 01, 2022 07:00 ET | Avalo Therapeutics
Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of AVTX-007, currently in Phase 1b ROCKVILLE, Md....
Avalo-Final_Black-01.jpg
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
July 06, 2022 16:05 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company’s common stock, par value...
Avalo-Final_Black-01.jpg
Avalo to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 07:30 ET | Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present...